Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EXOZ

eXoZymes Inc

Apr 03 • 04:00PM ET

10.44

Dollar change +0.32
Percentage change 3.16	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	79.85%	Shs Outstand	8.37M	Perf Week	3.06%
Market Cap	87.38M	Forward P/E	-	EPS next Y	-	Insider Trans	0.06%	Shs Float	1.69M	Perf Month	-38.95%
Income	-	PEG	-	EPS next Q	-	Inst Own	1.17%	Short Float	1.05%	Perf Quarter	-34.95%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-3.02%	Short Ratio	0.79	Perf Half Y	-
Book/sh	1.25	P/B	8.38	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf Year	-
Cash/sh	1.16	P/C	8.99	EPS next 5Y	-	ROE	-	52W Range	8.50 - 23.99	Perf YTD	-36.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-56.48%	Beta	-
Dividend TTM	-	Quick Ratio	8.12	Sales past 5Y	-	Gross Margin	-	52W Low	22.82%	ATR (14)	1.96
Dividend Ex-Date	-	Current Ratio	8.12	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	33.58	Volatility	11.83% 14.66%
Employees	31	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.11	EPS Q/Q	-	Payout	-	Rel Volume	0.31	Prev Close	10.12
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 02 AMC	Avg Volume	22.39K	Price	10.44
SMA20	-20.08%	SMA50	-31.57%	SMA200	-28.92%	Trades		Volume	6,877	Change	3.16%

Apr-02-25 04:10PM	eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO (GlobeNewswire)
04:05PM	eXoZymes Provides Fourth Quarter and Full Year 2024 Update (GlobeNewswire)
Mar-26-25 05:00PM	eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 (GlobeNewswire) -19.67%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire)
Feb-21-25 04:05PM	eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. (GlobeNewswire)
08:25AM	Loading…
Feb-19-25 08:25AM	eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering (GlobeNewswire)
Feb-10-25 11:00AM	Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol (GlobeNewswire)
Nov-19-24 09:05AM	Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities (GlobeNewswire) +14.54%
Nov-14-24 04:05PM	Invizyne Technologies Announces Closing of Initial Public Offering (GlobeNewswire) +19.77% +7.34%
Nov-13-24 04:05PM	Invizyne's Nasdaq IPO Marks New Era of Biomanufacturing (GlobeNewswire)
09:05AM	Invizyne Technologies Begins Trading on NASDAQ (GlobeNewswire)
Nov-12-24 10:52AM	Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024 (GlobeNewswire)

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heltzen Michael	Chief Executive Officer	Jan 17 '25	Buy	10.78	1,767	19,048	3,872	Jan 21 06:02 AM
Heltzen Michael	Chief Executive Officer	Jan 16 '25	Buy	10.72	121	1,297	2,105	Jan 21 06:02 AM
Heltzen Michael	Chief Executive Officer	Nov 15 '24	Buy	11.10	1,984	22,022	1,984	Nov 19 06:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXOZ

eXoZymes Inc

Upgrade your FINVIZ experience